This activity is hosted on the site of our educational partner

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

You will be connecting to our educational partner, which controls its own content, practices, and other policies.

  • Overview
  • Pre-Assessment
  • Activity
  • Post-Test
  • Evaluation
  • Claim Credit
Personalized Treatment for High-Risk and <em>FLT3</em>+ Relapsed or Refractory AML

Personalized Treatment for High-Risk and FLT3+ Relapsed or Refractory AML

Format

Webcast

Time to Complete

1 hour

Released

November 29, 2018

Expires

November 29, 2019
Add to Queue


Maximum Credits

1.00 / AMA PRA Category 1 CreditTM

Accredited Provider



Provided by Haymarket Medical Education

Commercial Supporter

Supported by an educational grant from Astellas Pharma US, Inc.

Program Description

Even with improvements in induction therapy, post-remission strategies, and in tolerability of treatment regimens for patients with acute myeloid leukemia (AML) over the last several decades, better overall survival and progression-free survival has remained an ongoing challenge. However, recently approved and emerging targeted agents for AML are expected to dramatically change the treatment landscape, especially with regard to high-risk and FLT3+ relapsed or refractory AML. Understanding the clinical evidence is necessary to define the strengths, limitations, and selection of each targeted drug, alone and in combination. Ultimately, delivering the right treatment to the right patient translates into a chance for deeper and more durable responses and the best possible outcome for each patient with AML.

Intended Audience

Hematologist-oncologists, oncology nurses, and advanced practitioners in oncology

Educational Objectives

After completing the activity, the participant should be better able to:

  • Utilize mutational analysis as indicated to guide treatment choice in AML
  • Identify the benefits and limitations of approved and emerging agents, including FLT3-targeted therapies
  • Apply effective patient-physician communication with shared decision-making about treatment choices to address psychosocial and emotional needs of the patient

Conflict Of Interest Disclosure Policies

In accordance with the ACCME Standards for Commercial Support, HME requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. HME resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational activities.

Faculty

Alexander E. Perl, MD (Chair)
Associate Professor of Medicine
Leukemia Program
Division of Hematology/Oncology
University of Pennsylvania
Philadelphia, PA

Dr. Perl receives consulting fees from Argo Pharmaceuticals, Astellas Pharma US, Inc., Daiichi-Sankyo Company Limited, Novartis Pharmaceuticals Corporation, and Pfizer Inc. He is on the advisory committees of Actinium Pharmaceuticals, Inc., and Asana Biosciences, LLC.

Naval G. Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, TX

Dr. Daver receives consulting fees from AbbVie Inc., Bristol-Myers Squibb Company, Daiichi-Sankyo Company Limited, Jazz Pharmaceuticals, Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical, Inc., and Pfizer Inc. He also receives contracted research funds from AbbVie Inc., Bristol-Myers Squibb Company, Daiichi-Sankyo Company Limited, Genentech, Inc., GlycoMimetics, Inc., Incyte Corporation, Karyopharm Therapeutics, Pfizer Inc., Servier, and Sunesis Pharmaceuticals, Inc.

Amir T. Fathi, MD
Assistant Professor of Medicine
Massachusetts General Hospital
Harvard School of Medicine
Boston, MA

Dr. Fathi receives consulting fees from Astellas Pharma US, Inc., Boston Biomedical, Celgene Corporation, Jazz Pharmaceuticals, and Takeda Pharmaceutical Company Ltd. He also receives contracted research funds from Agios Inc., Celgene Corporation, Seattle Genetics, Inc., and Takeda Pharmaceutical Company Ltd.

Accredited Provider Disclosure

Haymarket Medical Education staff involved in the planning and content review of this activity have no relevant financial relationships to disclose.

Credit

1.00

Type

AMA PRA Category 1 Credit(s)TM

Accreditation Statement

Haymarket Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Designation Statement

Haymarket Medical Education designates this enduring material for a maximum of 1.00 AMA PRA Category 1 CreditTM  .  Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Credit Information

Physician Assistant Continuing Education
AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME or a recognized state medical society. PAs may receive a maximum of 1.00 Category 1 Credits for completing this activity.

Nurse Practitioner Continuing Education
The American Academy of Nurse Practitioners Certification Program (AANPCP) accepts certificates of participation for educational activities certified for AMA PRA Category 1 CreditTM   from organizations accredited by ACCME. Individuals are responsible for checking with the AANPCP for further guidelines.

Disclosure of Unlabeled Use

This CME activity may or may not discuss investigational, unapproved, or off-label use of drugs. Participants are advised to consult prescribing information for any products discussed. The information provided in this CME activity is for continuing medical education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options for a specific patient's medical condition.

Disclaimer

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Haymarket Medical Education or Astellas Pharma US, Inc. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Instructions

To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.

If you have any questions relating to the CME accreditation of this activity, please contact please contact HME at cmequestions@haymarketmedical.com.

If you have any other questions relating to your certificate or other issues with the activity, please contact
myCME.Support@haymarketmedical.com.

Privacy Policy

SYSTEM REQUIREMENTS

Hardware and Software Requirements
  • A computer with an internet connection
  • Internet Browser: Internet Explorer 7.x or higher, Firefox 4.x or higher, Safari 2.x or higher, or any other W3C standards compliant browser
  • Additional Software: Adobe Flash Player and/or an HTML 5 capable browser maybe required for video or audio playback. PowerPoint or Adobe Acrobat Reader may occasionally be required
Add to Queue